Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in heavily pretreated patients with hematological malignancies. Hematol Meeting Rep. 2009;1(8). doi:10.4081/hmr.v1i8.297